Drug Profile
Research programme: hepatitis C therapies - Novita Healthcare/TargetDrug
Alternative Names: HCV therapies - Novita Healthcare/TargetDrugLatest Information Update: 24 Mar 2017
Price :
$50
*
At a glance
- Originator Avexa; TargetDrug
- Developer Novita Healthcare; TargetDrug
- Class Small molecules
- Mechanism of Action Hepatitis C virus replication inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Hepatitis C
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Hepatitis-C in Australia (PO)
- 16 Jul 2016 No recent reports of development identified for research development in Hepatitis-C in China (PO)
- 05 Aug 2009 Monogram Biosciences has been acquired by Laboratory Corporation of America Holdings